A recent research led by the researchers from the National Taiwan University College of Medicine and the Baylor College of Medicine have come up with a compound that can stop growth of cancer. The findings to the research that the drug flunarizine can reduce speed of the growth of triple-negative breast cancer in an animal model of the disease. The proof of the concept was published in the journal Scientific Reports that shows this approach can possibly lead to the discovery of drugs in such a manner that is faster and cheaper than traditional drug development strategies. Most importantly, screening of the FDA approved compounds for this concept.
According to co-corresponding author and an associate professor of molecular and cellular biology, Dr. Eric C. Chang and the Lester and Sue Smith Breast Center in the Dan L Duncan Comprehensive Cancer Center at Baylor, said that they focused on finding ways to disturb the effects of a class of proteins called Ras, which are key drivers of a variety of cancer. They further added that in this proof-of-concept study they have recognized a strategy to attack N-Ras for therapy. One of the very aggressive form of cancer N-Ras that drives a form of triple-negative breast cancer has no targeted therapy available.
Furthermore, Chang added that directly mixing Ras proteins is actually difficult but it is important because only Ras is capable of resisting to other forms of treatments targeting downstream pathways. Therefore, Chang and his colleagues sanctioned compounds that can minimize N-Ras quantity in cancer cells by changing the cell’s natural ability to reduce this protein.